SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Agapitov, A. V
Right arrow Articles by Haynes, W. G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agapitov, A. V
Right arrow Articles by Haynes, W. G
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Role of endothelin in cardiovascular disease

Alexei V Agapitov

Department of Internal Medicine, University of Iowa, Iowa City, USA

William G Haynes

Department of Internal Medicine, University of Iowa, Iowa City, USA, william-g-haynes{at}uiowa.edu

Endothelins are a family of peptides, which comprises endothelin-1 (ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3), each containing 21 amino-acids. ET-1 is a peptide secreted mostly by vascular endothelial cells, the predominant isoform expressed in vasculature and the most potent vasoconstrictor currently known. ET-1 also has inotropic, chemotactic and mitogenic properties. In addition, it influences salt and water homeostasis through its effects on the renin-angiotensin-aldosterone system (RAAS), vasopressin and atrial natriuretic peptide and stimulates the sympathetic nervous system.

The overall action of endothelin is to increase blood pressure and vascular tone. Therefore, endothelin antagonists may play an important role in the treatment of cardiac, vascular and renal diseases associated with regional or systemic vasoconstriction and cell proliferation, such as essential hypertension, pulmonary hypertension, chronic heart failure and chronic renal failure. Long-term anti-endothelin therapy may improve symptoms and favourably alter the progression of heart failure.

Endothelin appears to participate in induction and progression of sclerotic renal changes, leading to progression to end-stage renal disease. Anti-endothelin therapy might offer additional benefits in the prevention of progression of chronic renal failure in addition to the known benefits of RAAS inhibition.

Clinical trials have demonstrated potentially important benefits of endothelin antagonists for patients with essential hypertension, pulmonary hypertension and heart failure. Further studies are necessary to determine the role of anti-endothelin therapy in the treatment of cardiovascular diseases and determine the different roles of selective receptor antagonism vs. mixed ETA/B-receptor antagonism in human diseases.

Key Words: endothelium • endothelin • endothelin antagonists • hypertension • chronic heart failure

References

  • Moncada S., Grygewski R., Bunting S., Vane JR An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yanagisawa M., Kurihawa H., Kimura S. et al.A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Inoue A., Yanagisawa M., Kimura S. et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-7.[Abstract/Free Full Text]
  • Nakano A., Kishi F., Minami K., Wakabayashi H., Nakaya Y., Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 1997;159(4): 1987-92.[Abstract]
  • Inoue A., Yanagisawa M., Takuwa Y., Mitsui Y., Kobayashi M., Masaki T. The human preproendothelin-1 gene: complete nucleotide sequence and regulation of expression. J Biol Chem 1989;264:14954-9.[Abstract/Free Full Text]
  • Gray GA Generation of endothelin. In: Gray GA, Webb DJ (eds.). Molecular Biology and Pharmacology of the Endothelins. Austin: RG Landes, 1995:13-32.
  • Howard PG, Plumpton C., Davenport AP Anatomical localisation and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens 1992;10:1379-86.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Plumpton C., Champeney R.,Ashby MJ, Kuc RE, Davenport AP Characterization of endothelin isoforms in human heart: endothelin-2 demonstrated. J Cardiovasc Pharmacol 1993; 22(suppl 8):S26-S28.[Web of Science][Medline] [Order article via Infotrieve]
  • Hirata Y., Kanno K., Watanabe TX et al. Receptor binding and vasoconstrictor activity of big endothelin. Eur J Pharmacol 1990;176:225-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Xu D., Emoto N., Giaid A. et al. ECE-1:A membrane bound metalloprotease that catalyses the proteolytic activation of big endothelin-1. Cell 1994;78:473-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yoshimoto S., Ishizaki Y., SasakiT, Murota SI Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke 1991;22:378-83.[Abstract/Free Full Text]
  • Barnes K., Turner AJ Endothelin converting enzyme is located on alpha-actin filaments in smooth muscle cells. Cardiovasc Res 1999;42(3):814-22.[Abstract/Free Full Text]
  • Haynes WG, Webb DJ Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344:852-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sirviö ML, Metsärinne K., Saijonmaa, Fyrquist F. Tissue distribution and half-life of 125I-endothelin in the rats: importance of pulmonary clearance. Biochem Biophys Res Commun 1990;167:1191-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Löffler BM, Breu V., Clozel M. Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett 1993;333:108-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Plumpton C., Ferro CJ, Haynes WG, Webb DJ, Davenport AP The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 1996;119:311-14.[Web of Science][Medline] [Order article via Infotrieve]
  • Abassi ZA, Golomb E., Bridenhaugh R., Keiser HR Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11. Br J Pharmacol 1993;109:1024-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Ferro CJ, Spratt JC, Haynes WG, Webb DJ Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 1998;97:2323-30.[Abstract/Free Full Text]
  • Plumpton C., Haynes WG, Webb DJ, and Davenport AP Phosphoramide inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in human forearm. Br J Pharmacol 1995;116:1821-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Plumpton C., Haynes WG, Webb DJ, Davenport AP The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 1996;119:311-14.[Web of Science][Medline] [Order article via Infotrieve]
  • Arai H., Hori S.,Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348:730-2.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Williams DL, Jones KL, Pettibone DJ, Lis EV, Clineschmidt BV Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem Biophys Res Commun 1991;175:556-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hosoda K., Nakao K.,Arai H. et al. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 1991;287:23-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ihara M., Noguchi K., Saeki T. et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 1992;50:247-55.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ogawa Y., Nakao K.,Arai H. et al. Molecular cloning of a nonisopeptide-selective human endothelin receptor. Biochem Biophys Res Commun 1991;178:248-55.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kishi F., Minami K., Okishima N. et al. Novel 31-amino-acid-length endothelins cause constriction of vascular smooth muscle. Biochem Biophys Res Comm 1998;248(2):387-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Niwa Y., Nagata N., Oka M. et al. Production of nitric oxide from endothelial cells by 31-amino-acid-length endothelin-1, a novel vasoconstrictive product by human chymase. Life Sci 2000;67(9):1103-9.[CrossRef][Medline] [Order article via Infotrieve]
  • Davenport AP, Maguire JJ Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? Trends Pharmacol Sci 1994;15:9-11.[CrossRef][Medline] [Order article via Infotrieve]
  • Haynes WG, Strachan FE,Webb DJ Endothelin ETA and ETB receptors mediate vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995;92:357-63.[Abstract/Free Full Text]
  • Ishikawa K., Ihara M., Noguchi K. et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 1994; 91:4892-6.[Abstract/Free Full Text]
  • Roubert P., Gillard V., Plas P., Guillon JM, Chabrier PE, Braquet P. Angiotensin II and phorbol-esters potently down-regulate endothelin (ET-1) binding sites in vascular smooth muscle cells. Biochem Biophys Res Commun 1989;164:809-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Liu J., Chen R., Casley DJ, Nayler WN Ischemia and reperfusion increase 125I-labelled endothelin-1 binding in rat cardiac membranes. Am JPhysiol 1990;258:H829-H835.[Web of Science][Medline] [Order article via Infotrieve]
  • Nambi P., Pullen M., Contino LC, Brooks DP Upregulation of renal endothelin receptors in rats with cyclosporin A-induced nephrotoxicity. Eur J Pharmacol 1990;187:113-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • ResinkTJ, Scott-Burden T., Buhler FR Endothelin stimulates phospholipase C in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1988;157:1360-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Griendling KK, Tsuda T., Alexander RW Endothelin stimulates diacylglycerol accumulation and activates protein kinase C in cultured vascular smooth muscle cells. J Biol Chem 1989; 264:8237-40.[Abstract/Free Full Text]
  • Hirata Y., Yoshimi H., Takata S. et al. Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. Biochem Biophys Res Commun 1988;154:868-75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kodama M., Kanaide H.,Abe S., Hirano K., Kai H., Nakamura M. Endothelin-induced Ca-independent contraction of the porcine coronary artery. Biochem Biophys Res Commun 1989;160:1302-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cocks TM, Broughton A., Dib M., Sudhir K., Angus JA Endothelin is blood vessel selective: studies on a variety of human and dog vessels in vitro and on regional blood flow in the conscious rabbit. Clin Exp Pharmacol Physiol 1989; 16:243-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Cardillo C., Kilcoyne CM, Cannon RO 3rd, Panza JA Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 2000;35(6):1237-41.[Abstract/Free Full Text]
  • Clozel M., Clozel JP Effects of endothelin on regional blood flows in squirrel monkeys. J Pharmacol Exp Ther 1989; 250:1125-31.[Abstract/Free Full Text]
  • Mortensen LH, Fink GD Haemodynamic effect of human and rat endothelin administration into conscious rats. Am J Physiol 1990;258:H362-H368.[Web of Science][Medline] [Order article via Infotrieve]
  • Clarke JG, Benjamin N., Larkin SW, Webb DJ, Davies GJ, Maseri,A. Endothelin is a potent long-lasting vasoconstrictor in men. Am JPhysiol 1989;257:H2033-H2035.[Web of Science][Medline] [Order article via Infotrieve]
  • Cockcroft JR, Clarke JG, Webb DJThe effect of intra-arterial endothelin on resting blood flow and sympathetically mediated vasoconstriction in the forearm of man. Br J Clin Pharmacol 1991;31:521-4.[Web of Science][Medline] [Order article via Infotrieve]
  • Haynes WG,Webb DJ Endothelium-dependent modulation of responses to endothelin-1 in human veins. Clin Sci 1993; 84:427-33.[Web of Science][Medline] [Order article via Infotrieve]
  • Vierhapper H., Wagner OF, Nowotny P., Waldhäusl W. Effect of endothelin-1 in man. Circulation 1990;81:1415-18.[Abstract/Free Full Text]
  • Wagner OF, Vierhapper H., Gasic S., Nowotny P., Waldhäusl W. Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur J Clin Invest 1992; 22:277-82.[Web of Science][Medline] [Order article via Infotrieve]
  • Rabelink TJ, Kaasjager KAH, Boer P., Stroes EG, Braam B., Koomans HA Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 1994;46:376-81.[Web of Science][Medline] [Order article via Infotrieve]
  • Pernow J.,Ahlborg G., Lundberg JM, Kaijser L. Long-lasting coronary vasoconstrictor effects and myocardial uptake of endothelin-1 in humans. Acta Physiol Scand 1997;159:147-53. 50. Ishikawa T., Yanagisawa M., Kimura S., Goto K., Masaki T. Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. Am J Physiol 1988;255:H970-H973.[Web of Science][Medline] [Order article via Infotrieve]
  • Ezra D., Goldstein RE, Czaja JF, Feuerstein GZ Lethal ischaemia due to intracoronary endothelin in pigs. Am J Physiol 1989;257:H339-H343.[Web of Science][Medline] [Order article via Infotrieve]
  • De Nucci G., Thomas R., D'Orleans-Juste P. et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988;85:9797-800.[Abstract/Free Full Text]
  • Suzuki S., Kajikuri J., Suzuki A., Itoh T. Effects of endothelin-1 on endothelial cells in the porcine coronary artery. Circ Res 1991;69:1361-8.[Abstract/Free Full Text]
  • Jougasaki M., Schirger JA, Simari RD, Burnett JC Jr. Endothelin-B receptor activation of adrenomedullin production and release from cultured endothelial cells. Hospitalis 1998;68:8S.
  • McMahon EG, Palomo MA, Moore WM Phosphoramidon blocks the pressor activity of big endothelin[1-39] and lowers blood pressure in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1991;17(suppl 7):S29-S33.[CrossRef]
  • Pollock DM, Opgenorth TJ Evidence for endothelin-induced renal vasoconstriction independent of ETA receptor activation. Am J Physiol 1993;264: R222-R226.[Web of Science][Medline] [Order article via Infotrieve]
  • Clozel M., Breu V., Burri K. et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993; 365:759-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Véniant M., Clozel JP, Hess P., Clozel M. Endothelin plays a role in the maintenance of blood pressure in normotensive guinea pigs. Life Sci 1994;55:445-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gardiner SM, Compton AM, Kemp PA, Bennett T. The effects of phosphoramidon on the regional haemodynamic responses to human proendothelin [1-38] in conscious rats. Br J Pharmacol 1991;103:2009-15.[Web of Science][Medline] [Order article via Infotrieve]
  • Douglas SA, Elliot JD, Ohlstein EH Regional vasodilatation to endothelin-1 is mediated by a non-ETA receptor subtype in the anaesthetised rat: effect of BQ-123 on systemic haemodynamic responses.EurJPharmacol 1992;221:315-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cirino M., Battistini B.,Yano M., Rodger IW Dual cardiovascular effects of endothelin-1 dissociated by BQ-153, a novel ETA receptor antagonist. J Cardiovasc Pharmacol 1994; 24:587-94. 62. Warner TD, Allcock GH, Vane JR Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol 1994;112:207-13.[Web of Science][Medline] [Order article via Infotrieve]
  • Haynes WG, Ferro CE, O'Kane K., Somerville D., Lomax CL, Webb DJ Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in man. Circulation 1996;93:1860-70.[Abstract/Free Full Text]
  • Weber C., Schmitt R., Birnboeck H. et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharm Ther 1996; 60:124-37.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Verhaar MC, Strachan FE, Newby DE et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998;97:752-6.[Abstract/Free Full Text]
  • Fukuroda T., Fujikawa T., Ozaki S., Ishikawa K., Yano M., Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994; 199:1461-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gratton JP, Cournoyer G., Loffler BM, Sirois P., D'Orleans-Juste P. ETB receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit. Hypertension 1997;30:1204-9.[Abstract/Free Full Text]
  • Terada Y., Tomita K., Nonoguchi H., Marumo F. Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. J Clin Invest 1992; 90:107-12.[Web of Science][Medline] [Order article via Infotrieve]
  • Kohan DE, Padilla E. Osmolar regulation of endothelin-1 production by rat inner medullary collecting duct. J Clin Invest 1993;91:1235-40.[Web of Science][Medline] [Order article via Infotrieve]
  • Kohan DE, Hughes AK Autocrine role of endothelin-1 in rat IMCD: inhibition of AVP-induced cAMP accumulation. Am J Physiol 1993;265:F126-F129.[Web of Science][Medline] [Order article via Infotrieve]
  • Edwards RM, Trizna W., Ohlstein EH Renal microvascular effects of endothelin. Am J Physiol 1990;259:F217-F221.[Web of Science][Medline] [Order article via Infotrieve]
  • Firth JD, Ratcliffe PJ, Raine AE, Ledingham JG Endothelin:
  • López-Farré A., Montanes I., Millas I., López-Nova JM Effect of endothelin on renal function in rats. Eur J Pharmacol 1989;163:187-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • King AJ, Brenner BM, Anderson S. Endothelin: a potent renal and systemic vasoconstrictor peptide. Am J Physiol 1989; 256:F1051-F1058.[Web of Science][Medline] [Order article via Infotrieve]
  • Maguire JJ, Kuc RE, O'Reilly G., Davenport AP Vasoconstrictor endothelin receptors characterised in human renal artery and vein in vitro. BrJPharmacol 1994;113:49-54. 76. Schmetterer L., Dallinger S., Bobr B., Selenko N., Eichler HG, Wolzt M. Systemic and renal effects of an ET(A) receptor subtype-specific antagonist in healthy subjects. Br J Pharmacol 1998;124(5):930-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fleisch M., Sutsch G., Yan XW et al. Systemic, pulmonary, and renal haemodynamic effects of endothelin ETA/B-receptor blockade in patients with maintained left ventricular function. J Cardiovasc Pharmacol 2000;36:302-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zeidel ML, Brady HR, Kone BC, Gullans SR, Brenner BM Endothelin, a peptide inhibitor of sodium Na+-K+-ATPase, in intact renal tubular endothelial cells. Am J Physiol 1989; 257:C1101-C1107.[Web of Science][Medline] [Order article via Infotrieve]
  • Plato CF, Pollock DM, Garvin JL Endothelin inhibits thick ascending limb chloride flux via ET(B) receptor-mediated NO release. Am J Phys - Renal Fluid and Electrolyte Physiology 2000;279(2):F326-33.
  • Oishi R., Monoguchi H., Tomita K., Murumo F. Endothelin-1 inhibits AVP stimulated osmotic water permeability in rat inner medullary collecting duct. Am J Physiol 1991;261:F951-F956.[Web of Science][Medline] [Order article via Infotrieve]
  • Michel H., BäckerA., Meyer-Lehnert, Migas I., Kramer HJ Rat renal, aortic and pulmonary endothelin-1 receptors: effects of changes in sodium and water intake. Clin Sci 1993;85:593-7. 82. Kohan DE, Padilla E., Hughes AK Endothelin B receptor mediates ET-1 effects on cAMP and PGE2 accumulation in rat IMCD. Am J Physiol 1993;265:F670-F676.[Web of Science][Medline] [Order article via Infotrieve]
  • YukimuraT.,YamashitaY., Miura K. et al. Renal vasodilating and diuretic actions of a selective endothelin ETB receptor agonist, IRL1620. Eur J Pharmacol 1994;264:399-405.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gariepy CE, Ohuchi T., Williams SC, Richardson JA, Yanagisawa M. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 2000;105:925-33.[Web of Science][Medline] [Order article via Infotrieve]
  • Komuro I., Kurihara H., Sugiyama T., Yoshizumi M.,Takaku F., Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988; 238:249-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ito H., Hirata Y., Hiroe M. et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991;69:209-15.[Abstract/Free Full Text]
  • Badr KF, Murray JJ, Breyer MD, Takahashi K., Inagami T., Harris RC Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney: elucidation of signal transduction pathways. JClinInvest 1989;83:336-42.[Web of Science][Medline] [Order article via Infotrieve]
  • Nagata N., Niwa Y., Nakaya Y. A novel 31-amino-acid-length endothelin, ET-1 (1-31), can act as a biologically active peptide for vascular smooth muscle cells. Biochem Biophys Res Comm 2000;275(2):595-600.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yoshizumi M., Kim S., Kagami S. et al.Effect of endothelin-1 [1-31] on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells. Br J Pharmacol 1998;125(5):1019-27.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yoshizumi M., Kagami S., Suzaki Y. et al. Effect of endothelin-1 (1-31) on human mesangial cell proliferation. Jpn J Pharmacol 2000;84(2):146-55.[CrossRef][Medline] [Order article via Infotrieve]
  • Cunningham ME, Huribal M., Bala RJ, McMillen MA Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Crit Care Med 1997;25:958-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zouki C., Baron C., Fournier A., Filep JG Endothelin-1 enhances neutrophil adhesion to human coronary artery cells: role of ET(A) receptors and platelet-activating factor. Br J Pharmacol 1999;127(4):969-79.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kawaguchi H., Sawa H.,Yasuda H. Effect of endothelin on angiotensin converting enzyme in cultured pulmonary artery endothelial cells. J Hypertens 1991;9:171-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rakugi H., Tabuchi Y., Nakamaru M. et al. Endothelin activates the vascular renin-angiotensin system in rat mesenteric arteries. Biochem Int 1990;21:867-72.[Web of Science][Medline] [Order article via Infotrieve]
  • Cozza EN, Gomez-Sanchez CE, Foecking M., Chiou S. Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion. J Clin Invest 1989;84:1032-5.[Web of Science][Medline] [Order article via Infotrieve]
  • Boarder MR, Marriott DB Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells.JCardiovasc Pharmacol 1989;13(suppl 5):S223-S224.[Web of Science][Medline] [Order article via Infotrieve]
  • Barton M., Shaw S., Duscio LV, Moreau P., Luscher TF Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo - Role of ETA receptors for endothelin regulation. Biochem Biophys Res Comm 1997;238:861-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Moreau P., Duscio LV, Shaw S.,Takase H., Barton M., Luscher TF Angiotensin II increases tissue endothelin and induces vascular hypertrophy - reversal by ETA-receptor antagonist. Circulation 1997;96:1593-7.[Abstract/Free Full Text]
  • Herizi A., Jover B., Bouriquet N., Mimran A. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade.Hypertension 1998;31(1):10-4.[Abstract/Free Full Text]
  • Massart PE, Hodeige D., Van Mechelen H., Heyndrickx GR, Donckier J. Endothelin-1 receptor antagonism does not influence myocardial function in hypertensive dogs. Eur J Clin Invest 1998;28:798-806.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chillon JM, Heistad DD, Baumbach GL Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats.Hypertension 1996;27:794-8.[Abstract/Free Full Text]
  • Schiffrin EL, Sventek P., Li J-S., Turgeon A., Reudelhuber T. Anti-hypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. BrJPharmacol 1995;115:1377-81.[Web of Science][Medline] [Order article via Infotrieve]
  • Krum H., Viskoper RJ, Lacourciere Y., Budde M., Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998; 338:784-90.[Abstract/Free Full Text]
  • Duscio LV, Barton M., Shaw S., Moreau P., Luscher TF Structure and function of small arteries in salt-induced hypertension - Effects of chronic endothelin-subtype-A-receptor blockade. Hypertension 1997;30:905-11.[Abstract/Free Full Text]
  • Clozel M., Ramuz H., Clozel JP et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 1999;290:840-6.[Abstract/Free Full Text]
  • Pearl JM, Wellmann SA, McNamara JL et al. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function. Ann Thorac Surg 1999;68:1714-21.[Abstract/Free Full Text]
  • Williamson DJ, Wallman LL, Jones R. et al. Haemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000; 102:411-8.[Abstract/Free Full Text]
  • Channick RN, Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Marano G., Palazzesi S., Bernucci P., Grigioni M., Formigari R., Ballerini L. ET(A)/ET(B) receptor antagonist bosentan inhibits neointimal development in collared carotid arteries of rabbits. Life Sci 1998;63:PL259-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Okada K., NishidaY, Murakami H. et al. Role of endogenous endothelin in the development of graft atherosclerosis in rat cardiac allografts: antiproliferative effects of bosentan, a nonselective endothelin receptor antagonist. Circulation 1998; 97:2346-51.[Abstract/Free Full Text]
  • Kowala MC, Rose PM, Stein PD et al. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Path 1995;146:819-26.[Abstract]
  • Horkay F., Geller L., Kiss O. et al. Bosentan, the mixed endothelin-A- and -B-receptor antagonist, suppresses intrapericardial endothelin-1-induced ventricular arrhythmias. J Cardiovasc Pharmacol 2000;36(suppl 1):S320-2.[Web of Science][Medline] [Order article via Infotrieve]
  • Wenzel RR, Fleisch M., Shaw S. et al. Haemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998; 98:2235-40.[Abstract/Free Full Text]
  • Kirchengast M., Hergenroder S., Schult S., Munter K., Rubsamen K. Endothelin-1 and unstable angina: effect of either endothelin ET(A) or ET(B) receptor antagonism in a locally injured canine coronary artery. Eur J Pharmacol 1998; 341:187-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Best PJ, McKenna CJ, Hasdai D., Holmes DR Jr., Lerman A. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation 1999;99:1747-52.[Abstract/Free Full Text]
  • Honing ML, Hijmering ML, Ballard DE et al. Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans. J Am Soc Nephrol 2000;11:1498-504.[Abstract/Free Full Text]
  • Choussat R., Hittinger L., Barbe F., Maistre G., Carayon A., Crozatier B., Su J. Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs. Cardiovasc Res 1998;39:580-8.[Abstract/Free Full Text]
  • Mishima T.,Tanimura M., Suzuki G. et al. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart falure. J Am Coll Cardiol 2000; 35:222-9.[Abstract/Free Full Text]
  • Mulder P., Richard V., Derumeaux G. et al. Role of endogenous endothelin in chronic heart failure - effect of long-term treatment with an endothelin antagonist on survival, haemodynamics, and cardiac remodeling. Circulation 1997;96:1976-82.[Abstract/Free Full Text]
  • Sutsch G., Kiowski W., Yan XW et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998;98:2262-8.[Abstract/Free Full Text]
  • Sutsch G., Christen S.,Yan X-W. et al. Clinical and haemodynamic effects of an orally active endothelin-1 receptor antagonist in patients with refractory chronic heart failure. Circulation 1997;96(suppl I):I-93-I-94.
  • Mylona P., Cleland JG Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail 1999;1:197-200.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mulder P., Richard V., Bouchart F., Derumeaux G., Munter K., Thuillez C. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Cardiovasc Res 1998;39:600-8.[Abstract/Free Full Text]
  • Berger R., Stanek B., Hulsmann M. et al. Effects of endothelin A receptor blockade on endothelial function in patients with chronic heart failure. Circulation 2001;103:981-6.[Abstract/Free Full Text]
  • Spieker LE, Mitrovic V., Noll G. et al.Acute haemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol 2000;35:1745-52.[Abstract/Free Full Text]
  • Torre-Amione G., Durand JB, Nagueh S., Vooletich MT, Kobrin I., Pratt C.A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure. Chest 2001;120:460-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fujita K., Matsumura Y., Miyazaki Y.,Takaoka M., Morimoto S. Effects of the endothelin ETA-receptor antagonist FR139317 on development of hypertension and cardiovascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. Jpn J Pharmacol 1996;70:313-9.[Medline] [Order article via Infotrieve]
  • Stasch JP, Hirth-Dietrich C., Frobel K.,Wegner M. Prolonged endothelin blockade prevents hypertension and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Am J Hypertens 1995;8:1128-34.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Iwasaki T., Mihara S., Shimamura T. et al. Pharmacological characterization of PABSA, an orally active and highly potent endothelin-receptor antagonist. J Cardiovasc Pharmacol 1999;34:139-47.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Naruse M., Tanabe A., Naruse K. et al. Haemodynamic and biochemical effects of endothelin-A- and -B-receptor antagonist TAK-044 in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2000;36:S334-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Li JS, Knafo L., Turgeon A., Garcia R., Schiffrin EL Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol 1996; 271:H88-H93.[Web of Science][Medline] [Order article via Infotrieve]
  • Fraser TB, Mangos GJ, Turner SW, Whitworth JA Adrenocorticotrophic hormone-induced hypertension in the rat: effects of the endothelin antagonist bosentan. Clin Exp Pharmacol Physiol 1999;26:628-33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Miki S.,Takeda K., Kiyama M. et al.Augmented response of endothelin-A and endothelin-B receptor stimulation in coronary arteries of hypertensive hearts. J Cardiovasc Pharmacol 1998;31(suppl 1):S94-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yu M., GopalakrishnanV., McNeill JR Total peripheral conductance mediates antihypertensive effect of nonpeptide mixed endothelin receptor antagonist in deoxycorticosterone acetate-salt hypertensive rats. Am J Hypertens 1999;12:845-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Taddei S., Virdis A., Ghiadoni L., Sudano I., Notari M., Salvetti A. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999;100:1680-3.[Abstract/Free Full Text]
  • Cardillo C., Kilcoyne CM, Waclawiw M., Cannon RO 3rd, Panza JA Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999; 33:753-8.[Abstract/Free Full Text]
  • Herizi A., Belabbas H., Mimran A., Jover B. Cardiac and vascular hypertrophy in hypertension due to angiotensin II. Effect of losartan and bosentan. Archives des Maladies du Goeur et des Vaisseaux 2000;93:983-6.
  • Franco-Cereceda A., Holm P. Selective or nonselective endothelin antagonists in porcine hypoxic pulmonary hypertension? J Cardiovasc Pharmacol 1998;31(suppl 1):S447-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Miyahara T., Koizumi T., Kubo K. et al. Endothelin receptor blockade attenuates air embolization-induced pulmonary hypertension in sheep. EurJPharmacol 1999;385:163-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ueno M., Miyauchi T., Sakai S., Goto K., Yamaguchi I. Endothelin-A-receptor antagonist and oral prostacyclin analog are comparably effective in ameliorating pulmonary hypertension and right ventricular hypertrophy in rats. J Cardiovasc Pharmacol 2000;36(suppl 1):S305-10.[Web of Science][Medline] [Order article via Infotrieve]
  • Wedgwood S., McMullan DM, Bekker JM, Fineman JR, Black SM Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy. Circ Res 2001;89:357-64.[Abstract/Free Full Text]
  • Tilton RG, Munsch CL, Sherwood SJ et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Pulm Pharmacol Ther 2000;13:87-97.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Giaid A., Yanagisawa M., Langleben et al. Expression of endothelin-1 in lungs of patients with pulmonary hypertension. NEnglJMed 1993;328:1732-9.[Abstract/Free Full Text]
  • Prendergast B., Newby DE,Wilson LE, Webb DJ, Mankad PS Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery. Heart 1999;82:505-8.[Abstract/Free Full Text]
  • Yang Z., Krasnici N., Luscher T. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 1999;100:5-8.[Abstract/Free Full Text]
  • Hafizi S., Allen SP, Goodwin AT, Chester AH, Yacoub MH Endothelin-1 stimulates proliferation of human coronary smooth muscle cells via the ET(A) receptor and is co-mitogenic with growth factors. Atherosclerosis 1999;146:351-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tanaka Y., Makiyama Y., Mitsui Y. Endothelin-1 is involved in the growth promotion of vascular smooth muscle cells by hyaluronic acid. Intl J Cardiol 2000;76:39-47.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Umekawa K., Hasegawa H.,TsutsumiY, Sato K., MatsumuraY, Ohashi N. Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme. Jpn J Pharmacol 2000;84:7-15.[CrossRef][Medline] [Order article via Infotrieve]
  • Maxwell L., Harrison WR, Gavin JB Endothelin antagonists diminish postischemic microvascular incompetence and necrosis in the heart. Microvasc Res 2000;59:204-12.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Iimuro M., Kaneko M., Matsumoto Y., Fujise Y., Watanabe T., Hayashi H. Effects of an endothelin receptor antagonist TAK-044 on myocardial energy metabolism in ischemia/reperfused rat hearts.J Cardiovasc Pharmacol 2000;35:403-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kawabata H., Ryomoto T., Ishikawa K. Effect of an endothelin receptor antagonist and an angiotensin converting enzyme inhibitor on metabolism and contraction in the ischemic and reperfused rabbit heart. Jpn Circl 1999;63:770-4.[CrossRef]
  • Geshi E., Nomizo A.,ArataY., Nakatani M., Katagiri T. Effect of non-selective endothelin blockade, TAK-044, on the ischemic cellular injury of rat heart. Basic Res Cardiol 1999;94:94-101.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Szabo G., Fazekas L., Bahrle S. et al. Endothelin-A and -B antagonists protect myocardial and endothelial function after ischemia/reperfusion in a rat heart transplantation model. Cardiovasc Res 1998;39:683-90.[Abstract/Free Full Text]
  • Szabo G., Bahrle S., Fazekas L. et al. Endothelin-A receptor antagonist BQ123 protects against myocardial and endothelial reperfusion injury. Thorac Cardiovasc Surg 1998;46:232-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Zhang Y., Oliver JR, Horowitz JD Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist. Cardiovasc Res 1998;39:665-73.[Abstract/Free Full Text]
  • Omland T., Terje LR, Aakvaag A., Aarsland T., Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994;89:1573-9.[Abstract/Free Full Text]
  • TalbodecA, Berkane N., Blandin V. et al.Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. Mol Pharmacol 2000;57:797-804.[Abstract/Free Full Text]
  • Sharif I., Kane KA, Wainwright CL Endothelin and ischaemic arrhythmias-antiarrhythmic or arrhythmogenic? Cardiovasc Res 1998;39:625-32.[Abstract/Free Full Text]
  • Alexiou K., Dschietzig T., Simsch O. et al. Arrhythmogenic effects induced by coronary conversion of pulmonary big-endothelin to endothelin: aggravation of this phenomenon in heritable hyperlipidemia. J Am Coll Cardiol 1998;32:1773-8.[Abstract/Free Full Text]
  • Krassoi I., Pataricza J., Torday LL, Kun A., Papp JG Improvement by phosphoramidon of damaged endothelial function in porcine coronary artery. Ann Thorac Surg 2000; 70:878-82.[Abstract/Free Full Text]
  • Hasdai D., Best PJ, Cannan CR et al. Acute endothelin-receptor inhibition does not attenuate acetylcholine-induced coronary vasoconstriction in experimental hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998;18:108-13.[Abstract/Free Full Text]
  • Cardillo C., Kilcoyne CM, Cannon RO 3rd, Panza JA Increased activity of endogenous endothelin in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:1483-8.[Abstract/Free Full Text]
  • DeFily DV, Nishikawa Y., Chilian WM Endothelin antagonists block alpha1-adrenergic constriction of coronary arterioles. Am J Physiol 1999;276:H1028-34.[Web of Science][Medline] [Order article via Infotrieve]
  • Kyriakides ZS, Kremastinos DT, Psychari SN, Kolettis T., Sbarouni E., Webb DJ Coronary vasoconstriction after coronary angioplasty is attenuated by endothelin A receptor antagonism. Am J Cardiol 2001;87:1011-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kyriakides ZS, Kremastinos DT, Kolettis TM, Tasouli A., Antoniadis A., Webb DJAcute endothelin-A receptor antagonism prevents normal reduction of myocardial ischemia on repeated balloon inflations during angioplasty. Circulation 2000; 102:1937-43.[Abstract/Free Full Text]
  • Brooks DP, Contino LC, Storer B., Ohlstein EH Increased endothelin excretion in rats with renal failure induced by partial nephrectomy. Br J Pharmacol 1991;104:987-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Orisio S., Benigni A., Bruzzi I. et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993;43:354-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Nakamura T., Fukui M., Ebihara I. et al. Effects of a low protein diet on glomerular endothelin family gene expression in experimental focal glomerular sclerosis. Clin Sci 1995; 88:29-37.[Web of Science][Medline] [Order article via Infotrieve]
  • Mazzocchi G., Rossi GP, Malendowicz LK, Champion HC, Nussdorfer GG Endothelin-1 (1-31), acting as an ETA-receptor selective agonist, stimulates proliferation of cultured rat zona glomerulosa cells. FEBS Lett 2000;487:194-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Orth SR,Amann K., Gehlen F. et al.Adult human mesangial cells express endothelin-B-receptors which mediate endothelin-1-induced cell growth. J Cardiovasc Pharmacol 2000;36(suppl 1):S232-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001;37:490-6.[Abstract/Free Full Text]
  • Muller DN, Mervaala EM, Schmidt F. et al. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 2000; 36:282-90.[Abstract/Free Full Text]
  • Ruggenenti P., Perna A., Mosconi L. et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. Kidney Int 1997;52(suppl 63):S54-S57.
  • Koyama H.,Tabata T.,Nishzawa Y.,Inoue T.,Morii H.,Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet 1989;333:991-2.[CrossRef]
  • Cao Z., Cooper ME, Wu LL et al. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. Hypertension 2000; 36:561-8.[Abstract/Free Full Text]
  • Matsumura Y., Kuro T., Kobayashi Y., Umekawa K., Ohashi N., Takaoka M. Protective effect of SM-19712, a novel and potent endothelin converting enzyme inhibitor, on ischemic acute renal failure in rats.Jpn JPharmacol 2000;84:16-24.[CrossRef][Medline] [Order article via Infotrieve]
  • Ergul A., Grubbs AL, Zhang Y., Spinale FG Selective upregulation of endothelin converting enzyme-1a in the human failing heart. Journal of Cardiac Failure 2000;6:314-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yamauchi-Kohno R., Miyauchi T., Hoshino T. et al. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Circulation 1999;99:2171-6.[Abstract/Free Full Text]
  • Sakai S., Miyauchi T., Kobayashi T., Yamaguchi I., Goto K., Sugishita Y. Altered expression of isoforms of myosin heavy chain mRNA in the failing rat heart is ameliorated by chronic treatment with an endothelin receptor antagonist. J Cardiovasc Pharmacol 1998;31(suppl 1):S302-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sakai S., Miyauchi T., Yamaguchi I. Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure. Circulation 2000;101:2849-53.[Abstract/Free Full Text]
  • Fontaine ER, Viau S., Jasmin G., Dumont L. Effects of phosphoramidon, BQ 788, and BQ 123 on coronary and cardiac dysfunctions of the failing hamster heart. J Cardiovasc Pharmacol 1998;32:12-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tojo T., Tsunoda Y., Nakada S., Tomoike H. Effects of long-term treatment with nonselective endothelin receptor antagonist,TAK-044, on remodeling of cardiovascular system with sustained volume overload. J Cardiovasc Pharmacol 2000;35: 777-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • New RB, Sampson AC, King MK et al. Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance. Circulation 2000;102:1447-53.[Abstract/Free Full Text]
  • Ohnishi M., Wada A., Tsutamoto T., Fukai D., Kinoshita M. Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure. Cardiovasc Res 1998;39:617-24.[Abstract/Free Full Text]
  • Sakai S., Miyauchi T., Kobayashi M., Yamaguchi I., Goto K., Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384:353-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McMurray JJ, Ray SG, Abdullah I., Dargie HJ, Morton JJ Plasma endothelin in chronic heart failure. Circulation 1992; 85:1374-9.[Abstract/Free Full Text]
  • Pacher R., Bergler-Klein J., Globits S. et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 1993;71:1293-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schalcher C., Cotter G., Reisin L. et al. The dual endothelin receptor antagonist tezosentan acutely improves haemodynamic parameters in patients with advanced heart failure. Am Heart J2001; 142: 340-9.
  • Torre-Amione G., Young JB, Durand JB et al. Haemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001;103:973-80.[Abstract/Free Full Text]
  • MacCarthy PA, Grocott-Mason R., Prendergast BD, Shah AM Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 2000;101:142-7.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 1, 1-15 (2002)
DOI: 10.3317/jraas.2002.001
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 In VivoHome page
A. GLUBA, M. BANACH, D. P. MIKHAILIDIS, and J. RYSZ
Genetic Determinants of Cardiovascular Disease: The Renin-Angiotensin-Aldosterone System, Paraoxonases, Endothelin-1, Nitric Oxide Synthase and Adrenergic Receptors
In Vivo, September 1, 2009; 23(5): 797 - 812.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Mori, M. Amano, M. Takefuji, K. Kato, Y. Morita, T. Nishioka, Y. Matsuura, T. Murohara, and K. Kaibuchi
Rho-kinase Contributes to Sustained RhoA Activation through Phosphorylation of p190A RhoGAP
J. Biol. Chem., February 20, 2009; 284(8): 5067 - 5076.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
K. J. Allahdadi, T. W. Cherng, H. Pai, A. Q. Silva, B. R. Walker, L. D. Nelin, and N. L. Kanagy
Endothelin type A receptor antagonist normalizes blood pressure in rats exposed to eucapnic intermittent hypoxia
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H434 - H440.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. Papassotiriou, N. G. Morgenthaler, J. Struck, C. Alonso, and A. Bergmann
Immunoluminometric Assay for Measurement of the C-Terminal Endothelin-1 Precursor Fragment in Human Plasma
Clin. Chem., June 1, 2006; 52(6): 1144 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. Just, A. J. M. Olson, J. R. Falck, and W. J. Arendshorst
NO and NO-independent mechanisms mediate ETB receptor buffering of ET-1-induced renal vasoconstriction in the rat
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2005; 288(5): R1168 - R1177.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Rich and V. V. McLaughlin
Endothelin Receptor Blockers in Cardiovascular Disease
Circulation, November 4, 2003; 108(18): 2184 - 2190.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. L. Gumz, M. P. Popp, C. S. Wingo, and B. D. Cain
Early transcriptional effects of aldosterone in a mouse inner medullary collecting duct cell line
Am J Physiol Renal Physiol, October 1, 2003; 285(4): F664 - F673.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Agapitov, A. V
Right arrow Articles by Haynes, W. G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agapitov, A. V
Right arrow Articles by Haynes, W. G
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement